Foundry Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Foundry Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-131,885	Closed	-$6.07M	–	450
2016 Q3	$6.07M	Sell	131,885 -74,707	-36%	-$3.9M	0.32%	113
2016 Q2	$10.4M	Sell	206,592 -22,265	-10%	-$1.19M	0.59%	42
2016 Q1	$12.2M	Buy	228,857 +14,715	+7%	+$863K	1.21%	19
2015 Q4	$14.1M	Sell	214,142 -3,045	-1%	-$188K	1.17%	20
2015 Q3	$12.3M	Sell	217,187 -64,730	-23%	-$4.2M	1.07%	22
2015 Q2	$16.7M	Buy	281,917 +18,916	+7%	+$1.17M	1.33%	11
2015 Q1	$16.4M	Buy	263,001 +47,211	+22%	+$2.74M	1.36%	10
2014 Q4	$12.4M	Buy	215,790 +76,121	+55%	+$4.24M	1.02%	29
2014 Q3	$7.51M	Buy	139,669 +25,215	+22%	+$1.34M	0.7%	57
2014 Q2	$6M	Sell	114,454 -4,208	-4%	-$215K	0.56%	83
2014 Q1	$6.27M	Sell	118,662 -5,456	-4%	-$252K	0.59%	74
2013 Q4	$4.97M	Buy	+124,118	New	+$4.89M	0.45%	87

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Foundry Partners's TEVA Position: Q4 2016 in Review

Foundry Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 131,885 shares — an estimated $6.07M sold.

Foundry Partners first reported a position in TEVA in Q4 2013 and held it in 12 quarters. The position peaked at $16.7M in Q2 2015. 739 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Foundry Partners reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Foundry Partners sold 131,885 Teva Pharmaceuticals shares in Q4 2016, an estimated $6.07M.
Foundry Partners first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 12 quarters.
Foundry Partners's Teva Pharmaceuticals position peaked at $16.7M in Q2 2015.
739 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Foundry Partners's 13F filing for Q4 2016, filed 10 Feb 2017.